A unique paclitaxel-mediated modulation of the catalytic activity of topoisomerase IIα

Anti-Cancer Drugs

Volumn 10, Issue 4, 1999, Pages 397-404

  Dhawan, Vijender ^a   Swaffar, Diane Shomin ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Distamycin; Kdna decatenation assay; Paclitaxel; Pbr322 relaxation assay; Taxol, topoisomerase ii

Indexed keywords

AMSACRINE; DNA; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; ISOENZYME; PACLITAXEL; TUMOR ANTIGEN;

ANIMAL; ARTICLE; CATALYSIS; CATTLE; CHEMISTRY; CHO CELL; DRUG ANTAGONISM; HAMSTER; KINETICS; METABOLISM;

AMSACRINE; ANIMALS; ANTIGENS, NEOPLASM; CATALYSIS; CATTLE; CHO CELLS; CRICETINAE; DNA; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ISOENZYMES; KINETICS; PACLITAXEL;

EID: 0033112222     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199904000-00008     Document Type: Article

References (26)

1. Horwitz SB. Paclitaxel (Taxoi): mechanism of action. Ann Oncol 1994; 5 (suppl. 6): S3-6.
2. Pommier Y, Fesan MR, Goldwasser F. Topoisomerase inliibitors. In: Chabner BA, Longo LA, eds. Cancer chemotherapy and biotberapy, 2nd edn. Philadelphia: Uppincott-Raven 1996: 435-61.
3. Boege F. Analysis of eukaroytic DNA topoisomerase and topoisomerase-directed drug effects. Eur J Clin Chem Biochem 1996; 34: 873-88.
4. Swaffar DS, Ireland CM, Barrows LR. A rapid mechanism-based screen to detect potential anti-cancer agents. Anti-Cancer Drugs 1994; 5: 15-23.
5. Jeggo PA, Sedgwick SG, Kemp LM. X-ray sensitive mutants of CHO cells defective in double strand break rejoining. Mutât Res 1983; 112: 313-27.
6. 6-guanine alkylation. Carcinogenesis 1987; 8: 1853-9.
7. Jeggo PA, Caldecott K, Pidsley S, Banks GR. Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors. Cancer Res 1989; 49: 7057-63.
8. Warters RL, Lyons BW, U TM. Topoisomerase n activity in a DNA double strand repair deficient Chinese hamster ovary cell line. Mutât Res 1991; 254: 167-74.
9. Povirk LF. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Mutât Res 1996; 355: 71-89.
10. Barrows LR, Radisky DC, Swaffar DS, Copp BR, et al. Makaluvamines, marine natural products, are active anticancer agents and DNA topo II inhibitors. AntiCancer Drug Des 1993; 8: 333-47.
11. Taccioli GE, Rathbun G, Oltz E, Stamato T, et al. Impairment of V(D)J recombination in double-strand break repair mutants. Science 1993; 260: 207-10.
12. Osheroff N, Shelton ER, Brutlag DL DNA topoisomerase n from Drosophila melanogaster. relaxation of supercoiled DNA-JBtoICbein 1983; 258: 9536-43.
13. Woynarowski JM, McHugh M, Sigmund RD, Beerman TA. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoeclist 33258 and 4′,6-diamidine-2-phenyiindoIe. Mol Phannacol 1989; 35: 177-82.
14. Fesan Al, Pommier Y. Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamycin in simian virus 40 DNA. J Biol Cbem 1989; 264: 11354-9.
15. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-8.
16. Waring MJ. DNA modification and cancer. Annu Rev Biochem 1981; 50: 159-92.
17. Sorensen BS, Sinding J, Anderson AH, Alsner J, et al. Alode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA cleavage and religation events. J Mol Biol 1992; 228: 778-86.
18. Froelich-Ammon SJ, Patchan A1W, Osheroff N, Thompson RB. Topoisomerase II binds to ellipticine in the absence or presence of DNA. J Biol Cbem 1995, 270: 149985004.
19. Roca J, Isliida R, Berger JM, Andoh T, et al. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Set USA 1994; 91: 1781-5.
20. Burdan DA, Kingma PS, Froelich-Ammon SJ, Thompson RB, et al. Topoisomerase II-etoposide interactions direct the formation of drug induced enzyme-cleavage complexes. J Biol Cbem 1996; 271: 29238-44.
21. Guan J, Zhu XK, Tacliibana Y, Bastow KF, et al. Antitumor agents. 185. Synthesis and biological evaluation of tridemethylthiocolchicine analogs as novel topoisomerase II inhibitors. J Med Cbem 1998; 41: 1956-61.
22. Ishida R, Tetsuo M, Narita T, Yui R, et al. Inhibition of intracellular topoisomerase II by amitumor bis(2,6doxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991; 51: 4909-16.
23. Osheroff N, Corbett AH, Hsea SH, Westergaard M. Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes. Cancer Cbemotber Pbannacol 1994; 34: S19-25.
24. Halligan BD, Edwards KA, Liu LF. Purification and characterization of a type II DNA topoisomerase from bovine calf thymus.J Biol Cbem 1985; 260: 2475-82.
25. Rowinsky EK, Donehower RC. Antimicrotubule agents. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biothcrapy, 2nd edn. Pliiladelpliia: Lippincott-Raven 1996: 263-96.
26. Jordan MA, Wendall K, Gardiner S, Wilson L, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56: 816-25.